CAR-T Cell Discovery Empowering Precision in Cancer Therapy
Accelerating CAR-T Cells Discovery
With Single-Cell Functional Screening
tell us what you need, and we will deliver to you
CAR-T Cell
A personalized and highly targeted approach to cancer treatment, offering new hope for patients with challenging cancer types
CAR-T Cell Discovery and Engineering Process
CAR-T Cell Discovery Technology
Our platform directly screens for single-cell function and can automatically retrieve hitsfor sequencing to greatly accelerate the target discovery process.
CAR-Library Generation and Screening
Our Platform Provides Powerful Cellular Insights to Advance the Development and Testing of Adoptive Cell Therapies
Adapted from: Accelerating CAR and TCR Discovery with Single-Cell Functional Screening. 2023 Bruker Corporation
CAR-T cell therapy is an innovative cancer treatment that harnesses the power of the immune system.
T cells are extracted from a patient, are genetically modified to express chimeric antigen receptors (CARs) that specifically target cancer cells and are then reinfused into the patient. Once inside the body, CAR-T cells bind to antigens on the surface of cancer cells and trigger a powerful immune response, leading to the destruction of the cancer cells.
This personalized therapy offers a highly targeted and effective approach to treating certain cancers.
Discovery Workflow
Our platform allows directly screen TCR, CAR, T cell, target cell, patient cell, or peptide libraries to visualize cellular functionality.
Example of library sources include T cells from vaccinated individuals, peptides from databases, and cancer cells from tumors.
Screening these libraries on our platform, allows us to precisely co-culture a cell with a target to assess interactions and functionality by measuring cytotoxicity, cytokine secretions, and surface markers.
Functional contents can then be retrieved and sequenced to discover successful targeting modalities and useful targets for therapeutics.
Adapted from: Accelerating CAR and TCR Discovery with Single-Cell FunctionalScreening. 2023 Bruker Corporation
Our Services
.jpg)
Target Identification and Validation
Target Antigen Discovery
Identifying specific antigens on the surface of cancer cells that can be targeted by CAR-T cells is crucial. This involves bioinformatics analysis, proteomics, and genomics to discover and validate novel targets.
Preclinical Validation
Assessing the expression of the target antigen in cancer versus normal tissues to ensure specificity and reduce off-target effects.
CAR Design and Optimization
CAR Construct Design
Engineering the CAR construct, including the extracellular antigen-binding domain (usually derived from an antibody), hinge region, transmembrane domain, and intracellular signalling domains.
Optimization of CAR Constructs
Modifying CARs to improve their affinity, specificity, signalling strength, and persistence in the patient’s body.
Vector Development and Production
Lentiviral or Retroviral Vector Design
Creating viral vectors for efficient gene transfer into T cells. The design process ensures stable integration and expression of the CAR gene.
Vector Manufacturing
Producing clinical-grade viral vectors under quality conditions.
T Cell Isolation and Engineering
Patient T Cell Collection (Apheresis)
Isolating T cells from the patient’s blood through a process called apheresis.
T Cell Activation and Transduction
Activating T cells and transducing them with the CAR gene using viral vectors. This step involves precise protocols to maximize transduction efficiency and T cell viability.
CAR-T Cell Expansion and
Quality Control
Cell Expansion
Expanding the engineered CAR-T cells to clinically relevant numbers while maintaining their functionality and potency.
Quality Control Testing
Conducting rigorous testing to ensure CAR-T cells meet quality and safety standards. This includes assessing purity, viability, potency, and absence of contaminants.
Preclinical Studies
In Vitro Assays
Testing the CAR-T cells in vitro to evaluate their ability to recognize and kill target cancer cells.
In Vivo Models
Using animal models to assess the efficacy, safety, and biodistribution of the CAR-T cells. These studies help to understand the potential therapeutic effects and risks.